Predicting anxiety responses to halogenated glucocorticoid drugs using the hexobarbital sleep time test. (3rd July 2016)

• Record Type: Journal Article
• Authors: Tseilikman, Olga B.; Kozochkin, Denis A.; Manukhina, Eugenia B.; Downey, H. Fred; Misharina, Maria E.; Komelkova, Maria V.; Nikitina, Anna A.; Golodnii, Svyatoslav V.; Dodohova, Margarita A.; Tseilikman, Vadim E.
• Is Part Of: Stress. Volume 19:Number 4(2016:Jul.)
• Page Start: 390
• Page End: 394
• Publication Date: 2016-07-03
• Subjects: Anxiety -- cytochrome P450 -- glucocorticoids -- hexobarbital -- monoamine oxidase A -- serotonin; Stress (Physiology) -- Periodicals; 616.98
• DOI: 10.1080/10253890.2016.1183118
• Languages: English
• ISSNs: 1025-3890

Abstract

Abstract: Glucocorticoids (GCs) are used to treat numerous diseases, but their use in limited by adverse side effects. One such effect is occasional increased anxiety. Since the intensity of hepatic microsomal oxidation has been shown to alter responses to GC, we examined the possibility that rats with lower rates of hepatic GC metabolism would have increased anxiety. We hypothesized that the resulting, excessive GC would stimulate brain monoamine oxidase A (MAO-A), which would reduce brain serotonin, and thereby increase anxiety. Hepatic microsomal oxidative intensity was evaluated by the hexobarbital sleep time (HST) test. Results showed that rats with lower rates of hepatic GC metabolism had elevated brain MAO-A activity, reduced brain serotonin, and more anxiety than rats with higher rates of hepatic GC metabolism. We suggest that the HST test, as an integrative test of microsomal oxidation status, should be useful for predicting individual sensitivity to GC and to other drugs metabolized by the hepatic microsomal oxidation system.